- Vivacta 100 Guillat Avenue Kent Science Park Sittingbourne Kent ME9 8GU United Kingdom
23 June 2009 - Vivacta has closed a USD4.5m (GBP2.8m) financing round to commercialise piezofilm technology.
The benefits of using piezofilm detection technology at the point-of-care are described on a new website launched by Vivacta.
Vivacta's ultrasensitive point-of-care immunochemistry system has achieved compliance with ISO 13485:2003
Vivacta prepares for pilot manufacture of its highly sensitive, disposable piezofilm sensors for point of care (PoC) diagnostics by acquiring extra space and appointing an engineering manager
Vivacta says it is set to further strengthen its position in the point of care diagnostics market through two new appointments its board of directors